2017 Fiscal Year Final Research Report
lectin-derived from Maackia amurensis as a novel therapeutic option for treatment of skin diseases.
Project/Area Number |
15K08582
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Asahikawa Medical College |
Principal Investigator |
Honma Masaru 旭川医科大学, 医学部, 准教授 (50344578)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Keywords | podoplanin / 乾癬 / エンジュ / ポドプラニン |
Outline of Final Research Achievements |
MASL, a lectin-derived from Maackia amurensis, can work as a therapeutic agent on psoriasis via regulation of podoplanin-expression and the function. The precise functional mechanism has not been fully elucidated. However, results acquired in this study and safety of oral MASL administration to mice in previous reports suggest the possibility of MASL as a novel therapeutic option for the treatment of psoriasis.
|
Free Research Field |
皮膚科学
|